Last reviewed · How we verify
Revlimid
Revlimid is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently FDA-approved for Follicular lymphoma, Mantle cell lymphoma, Marginal zone lymphoma. Also known as: Lenalidomide, CC-5013, lénalidomide, lenalidomide.
Revlimid, also known as lenalidomide, is a medication used to treat multiple myeloma, smoldering myeloma, and various lymphomas, including Diffuse Large B-cell Lymphoma. It is typically taken orally, often in combination with dexamethasone, and is used as a first-line treatment for multiple myeloma.
At a glance
| Generic name | Revlimid |
|---|---|
| Also known as | Lenalidomide, CC-5013, lénalidomide, lenalidomide, Gemzar |
| Sponsor | M.D. Anderson Cancer Center |
| Target | Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
Common side effects
- Fatigue
- Diarrhea
- Asthenia
- Anemia
- Constipation
- Peripheral edema
- Neutropenia
- Back pain
- Nausea
- Insomnia
- Pyrexia
- Infection
Serious adverse events
- Neutropenia
- Thrombocytopenia
- Pneumonia
- DVT
- Dyspnea
- Hyperglycemia
- Leukopenia
- Lymphopenia
- Cataract
- Rash
Key clinical trials
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (PHASE1)
- Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma (PHASE3)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (PHASE1)
- Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (PHASE1)
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Revlimid CI brief — competitive landscape report
- Revlimid updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Revlimid
What is Revlimid?
What is Revlimid used for?
Who makes Revlimid?
Is Revlimid also known as anything else?
What development phase is Revlimid in?
What are the side effects of Revlimid?
What does Revlimid target?
Related
- Target: All drugs targeting Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Follicular lymphoma
- Indication: Drugs for Mantle cell lymphoma
- Indication: Drugs for Marginal zone lymphoma
- Also known as: Lenalidomide, CC-5013, lénalidomide, lenalidomide, Gemzar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing